“Healthcare reform measures, including the Inflation Reduction Act of 2022 (the “IRA”), may increase the difficulty and cost for us to obtain marketing approval for and commercialize our products, affect the prices we may set, and have a material adverse effect on our business and results of operations.”
All entries for: Coherus BioSciences
November 6, 2023
Coherus BioSciences
Negative Outlook
Camarillo, CA
201-500 employees
201-500 employees
Disease Area: Oncology
Drug Type: Biologic
August 2, 2023
Coherus BioSciences
Negative Outlook
Camarillo, CA
201-500 employees
201-500 employees
Disease Area: Oncology
Drug Type: Biologic
May 8, 2023
Coherus BioSciences
Negative Outlook
Camarillo, CA
201-500 employees
201-500 employees
Disease Area: Oncology
Drug Type: Biologic
November 8, 2022
Coherus BioSciences
Negative Outlook
Camarillo, CA
201-500 employees
201-500 employees
• “Material Adverse Effect”: “Healthcare reform measures, including the Inflation Reduction Act of 2022 (the “IRA”), may increase the difficulty and cost for us to obtain marketing approval for and commercialize our products, affect the prices we may set, and have a material adverse effect on our business and results of operations” • Concerns on Biosimilars: “…it is currently unclear how the IRA will be effectuated, and while the impact of the IRA on our business and the pharmaceutical industry cannot yet be fully determined, it is likely to be significant. In particular, if a product becomes subject to the IRA negotiation provision and related price cap, that may significantly alter the economic rationale for developing and commercializing a biosimilar.”
Disease Area: Oncology
Drug Type: Biologic